Celyad Oncology - CYAD Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $6.89
  • Forecasted Upside: 589.21 %
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.00
▼ -0.06 (-5.66%)

This chart shows the closing price for CYAD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Celyad Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYAD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYAD

Analyst Price Target is $6.89
▲ +589.21% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Celyad Oncology in the last 3 months. The average price target is $6.89, with a high forecast of $11.00 and a low forecast of $2.78. The average price target represents a 589.21% upside from the last price of $1.00.

This chart shows the closing price for CYAD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in Celyad Oncology. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
3/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2022William BlairDowngradeOutperform ➝ Market PerformLow
2/28/2022HC WainwrightDowngradeBuy ➝ Neutral$2.78High
1/11/2022Wells Fargo & CompanyLower TargetOverweight$20.00 ➝ $11.00Low
12/22/2021UBS GroupDowngradeNeutral ➝ SellHigh
12/10/2021HC WainwrightLower TargetBuy ➝ Buy$15.00 ➝ $13.00Low
8/20/2021JonestradingReiterated RatingHoldHigh
8/6/2021HC WainwrightLower TargetBuy$17.00 ➝ $15.00Low
5/10/2021HC WainwrightLower TargetBuy$18.00 ➝ $17.00Low
3/31/2021JonestradingReiterated RatingBuy ➝ HoldLow
3/25/2021JonestradingDowngradeBuy ➝ HoldMedium
12/8/2020HC WainwrightLower TargetBuy$22.00 ➝ $18.00Low
9/29/2020William BlairReiterated RatingBuyLow
6/1/2020William BlairReiterated RatingBuyMedium
5/7/2020HC WainwrightReiterated RatingBuyMedium
3/26/2020Wells Fargo & CompanyLower TargetOverweight$44.00 ➝ $20.00High
3/25/2020HC WainwrightLower TargetIn-Line ➝ Buy$43.00 ➝ $37.00Medium
12/11/2019HC WainwrightReiterated RatingBuy$43.00Low
11/22/2019HC WainwrightReiterated RatingBuy$43.00Medium
11/11/2019William BlairReiterated RatingOutperformMedium
9/4/2019William BlairReiterated RatingBuyLow
8/26/2019HC WainwrightReiterated RatingBuy$48.00Medium
8/23/2019William BlairReiterated RatingBuyLow
7/5/2019Piper Jaffray CompaniesLower TargetOverweight$41.00 ➝ $25.00Low
7/5/2019HC WainwrightReiterated RatingBuy ➝ Buy$52.00 ➝ $48.00Low
5/17/2019HC WainwrightReiterated RatingBuy$52.00Low
5/13/2019William BlairReiterated RatingBuyHigh
4/1/2019Piper Jaffray CompaniesLower TargetOverweight$51.00 ➝ $41.00Low
3/19/2019HC WainwrightBoost TargetBuy$46.00 ➝ $52.00High
3/18/2019William BlairReiterated RatingBuyHigh
12/4/2018William BlairReiterated RatingBuyLow
11/21/2018HC WainwrightReiterated RatingBuy$46.00High
11/12/2018William BlairReiterated RatingBuyLow
11/12/2018HC WainwrightReiterated RatingBuy$46.00Low
11/12/2018Piper Jaffray CompaniesLower TargetOverweight$51.00Low
10/30/2018William BlairInitiated CoverageOutperformLow
7/2/2018HC WainwrightInitiated CoverageBuy$45.00Medium
5/31/2018SunTrust BanksInitiated CoverageBuy$49.00High
5/25/2018Wells Fargo & CompanyInitiated CoverageOutperform$44.00Low
(Data available from 12/1/2017 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/5/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/4/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/4/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/3/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/1/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/1/2022

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Celyad Oncology logo
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Read More

Today's Range

Now: $1.00
Low: $0.97
High: $1.03

50 Day Range

MA: $1.14
Low: $0.95
High: $1.75

52 Week Range

Now: $1.00
Low: $0.95
High: $5.32

Volume

5,862 shs

Average Volume

47,898 shs

Market Capitalization

$22.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Celyad Oncology?

The following Wall Street sell-side analysts have issued stock ratings on Celyad Oncology in the last year: HC Wainwright, UBS Group AG, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for CYAD.

What is the current price target for Celyad Oncology?

2 Wall Street analysts have set twelve-month price targets for Celyad Oncology in the last year. Their average twelve-month price target is $6.89, suggesting a possible upside of 589.2%. Wells Fargo & Company has the highest price target set, predicting CYAD will reach $11.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.78 for Celyad Oncology in the next year.
View the latest price targets for CYAD.

What is the current consensus analyst rating for Celyad Oncology?

Celyad Oncology currently has 1 sell rating, 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CYAD, but not buy more shares or sell existing shares.
View the latest ratings for CYAD.

What other companies compete with Celyad Oncology?

How do I contact Celyad Oncology's investor relations team?

Celyad Oncology's physical mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The company's listed phone number is (210) 039-4100. The official website for Celyad Oncology is www.celyad.com. Learn More about contacing Celyad Oncology investor relations.